SL Science Holding Limited Ordinary Shares

Biotech & Genomic Medicine▲

SL Science Exhibits Preclinical Data Showing Gamma Delta T Cells Eradicate Glioblastoma

SL Science Holding Limited announced the successful exhibition of breakthrough preclinical research on a novel glioblastoma treatment at the 2026 World Congress of Basic and Clinical Pharmacology in Melbourne. The research, conducted with Taipei Medical University, JY BioMed, and HeXun Biosciences, showed that direct administration of gamma delta T cells achieved complete tumor elimination by day 26 post-treatment at the highest dose tested. The study demonstrated dose-dependent efficacy and a clean safety profile with no major adverse effects. SL Science's Chairman and CEO William Wang called the exhibition a monumental milestone, highlighting the platform's potential against challenging solid tumors.

SLBT ▲6986.TWO ▲

Biotech & Genomic Medicine

GlobeNewswire·63dRead more →

Biotech & Genomic Medicine▼

SL Science Holding reports full-year 2025 net loss of $3.82 million

SL Science Holding Limited reported a net loss of approximately $3.82 million for the full year ended December 31, 2025, compared to a net loss of approximately $1.19 million in the prior year. Net revenue decreased 35% to approximately $2.20 million, driven by a strategic shift from direct retail sales of exosome products to a wholesale model with corporate distributors in Taiwan. Research and development expenses remained robust at approximately $2.07 million, supporting the company's CD-19 Armed-T and Gamma Delta T cell therapy programs. The company completed its business combination with Horizon Space Acquisition II Corp. and listed on the Nasdaq Global Market under the ticker SLBT on June 12, 2026, concurrently closing a $7.8 million PIPE financing. As of December 31, 2025, restricted and unrestricted cash balances stood at approximately $1.26 million, down from approximately $4.14 million a year earlier.

SLBT ▼

Biotech & Genomic Medicine

GlobeNewswire·92dRead more →